<DOC>
	<DOCNO>NCT01126307</DOCNO>
	<brief_summary>Epilepsy one common chronic neurological disease , affect 300,000 Canadians . One 3 epilepsy patient refractory seizure mean antiseizure drug fail control seizure . This drug resistance epilepsy may relate expression multidrug resistance protein ( MDR ) . Varapamil inhibit MDR . We propose add verapamil/placebo patient ' anti epilepsy medication 3 month . Patients receive placebo verapamil add 3 month completion double-blind treatment period . Seizure frequency/severity track . Blood sample DNA collect . There 9 clinic visit 32 week . ECG echocardiogram do baseline repeat necessary</brief_summary>
	<brief_title>Study Verapamil Refractory Epilepsy</brief_title>
	<detailed_description>This open label study consist three phase : baseline , Double-blind treatment open-label-treatment . There 9 visit 32 week . During baseline period , number seizure record 2 month patient dose antiseizure drug ( ) previously establish provide good seizure control . Blood work , include blood DNA baseline ECG echocardiogram do may repeat necessary . During 3 month double-blind treatment phase , verapamil/placebo add current medication . Visits every 4 week . Vital sign , seizure count adverse event evaluate . All patient receive placebo offer 3 month open-label treatment verapamil .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Drug Resistant Epilepsy</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>1. patient seizure control antiseizure medication ; 2. must least 2 seizure per month . Exclusion : patient cardiovascular problem could adversely affect verapamil</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>refractory epilepsy- great 4 seizure 2 month baseline period</keyword>
</DOC>